

ASX RELEASE

2 January 2024

Change of Director's Interest Notice – Appendix 3Y: Jane Bell

Appendix 3Y Change of Director's Interest Notice for Mrs. Jane Bell is attached.

This ASX announcement was approved and authorised for release by the Company Secretary of Amplia Therapeutics Limited.

- End -

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/ampliatx)

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	AMPLIA THERAPEUTICS LIMITED
ABN	16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jane Catherine Bell
Date of last notice	7 September 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	31 December 2023
No. of securities held prior to change	Mrs Jane Catherine Bell 346,454 Ordinary Shares 23,097 ATXO Listed Options Ex Price \$0.28 Exp 31 Dec 2023 Mrs Jane Catherine Bell & Mr Geoffrey Bell <Schooner Super Fund A/C> 1,679,020 Ordinary Shares 49,493 ATXO Listed Options Ex Price \$0.28 Exp 31 Dec 2023 535,000 Unlisted Options Ex Price \$0.26 Exp 6 Sep 2025
Class	ATXO Listed Options Ex Price \$0.28 Exp 31 Dec 2023
Number acquired	Nil
Number disposed	72,590

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil – options expired unexercised
No. of securities held after change	Mrs Jane Catherine Bell 346,454 Ordinary Shares Mrs Jane Catherine Bell & Mr Geoffrey Bell <Schooner Super Fund A/C> 1,679,020 Ordinary Shares 535,000 Unlisted Options Ex Price \$0.26 Exp 6 Sep 2025
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	ATXO Listed Options Ex Price \$0.28 Exp 31 Dec 2023- options expired unexercised

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

2 January 2024

+ See chapter 19 for defined terms.